CEO Showcasing Ibuprofen Taste Masked Products

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

CEO Showcasing Ibuprofen Taste Masked Products

Oxford Pharmascience, the AIM-quoted specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces that CEO Marcelo Bravo will be showcasing for the first time its taste masked Ibuprofen OTC products which use the Company's proprietary delivery platform OXPzeroTM. Mr. Bravo will also be giving an overview of the Company and its programmes at the Proactive Investors One2One Investor Forum in London on 10th April at 6pm at Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB.

A copy of the presentation given will be made available on the Company's website after the event. Oxford Pharmascience has a diverse pipeline spanning pain relief (Non Steroidal Anti-Inflammatory Drugs or NSAIDs) and cardiovascular disease (Atorvastatin) indications with products aimed at both over-the-counter ("OTC") and prescription ("Rx") markets. The Company has two lead products that is beginning to commercialise this year, specifically a 200mg/5ml Ibuprofen suspension and 200mg soft 'gummie', both aimed at the OTC paediatrics market. These are the first products of their kind, completely taste and burn free. The Company is now establishing product supply both in Europe and North America with the aim of conducting preregistration bioequivalence trials of final versions of these products in early 2015. In parallel, the company is progressing its programmes in safer NSAIDs and safer statins as well as further NSAID OTC products.

NSAIDs and statins are some of the most widely used classes of drugs with known problems that affect patient adherence and ultimate therapeutic outcomes. The Company's portfolio addresses major unmet patient needs with significant commercial potential in global markets.

Marcelo Bravo, Chief Executive Officer of Oxford Pharmascience commented:

"I look forward to showcasing for the first time the lead products that Oxford Pharmascience is beginning to commercialise this year. We believe that our completely taste masked "burn free" high dose ibuprofen suspension and soft gummies are disruptive products in their category and signal Oxford Pharmascience's entrance in to the medicines market".

 For further information:

About Oxford Pharmascience Group Plc

Oxford Pharmascience uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (over the counter) branded portfolios.

Oxford Pharmascience focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance (adherence to a recommended course of treatment). By working with such medicines, the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.